In keeping our patients informed of the latest developments, I wanted to share with you a late breaking development.
We have been waiting since last year, at which time the FDA gave this medication a new "Breakthrough Designation" earlier in 2013.
As I previously noted, that patients with CLL generally are older, but regardless, all patients prefer a medication with less side effects.
Ibrutinib is an oral medication, with side effects including fatigue, increased risk of infection, but in general is better tolerated than other treatments. More importantly, the way in which the medication works is an entirely new approach. We are already securing this medication for some of our patients here in the clinic who were looking forward to this option.
